Consumption of Caffeinated Beverages and Kidney Function Decline in an Elderly Mediterranean Population with Metabolic Syndrome
View/ Open
Date
2021-03-31Author
Díaz López, Andrés
Paz Graniel, Indira
Ruiz, Verónica
Toledo, Estefanía
Becerra Tomás, Nerea
Corella, Dolores
Castañer, Olga
Martínez Hernández, José Alfredo
Wärnberg, Julia
Vioque, Jesús
Romaguera, Dora
López Miranda, José
Estruch, Ramón
Tinahones, Francisco J.
Lapetra, José
Serra Majem, Lluís
Bueno Cavanillas, Aurora
Tur, Josep A.
Martín Sánchez, Vicente
Pintó, Xavier
Delgado Rodríguez, Miguel
Matía Martín, Pilar
Vidal, Josep
Vázquez, Clotilde
Daimiel, Lidia
Fernández Villa, Tania
Ros, Emilio
Eguaras, Sonia
Babio, Nancy
Sorli, José Vicente
Goday, Albert
Abete, Itziar
Tojal Sierra, Lucas
Barón López, Francisco Javier
Torres Collado, Laura
Morey, Marga
García Ríos, Antonio
Casas, Rosa
Bernal López, María Rosa
Santos Lozano, José Manuel
Navarro, Adela
González, José I.
Zomeño Fajardo, María Dolores
Zulet, M. Ángeles
Vaquero Luna, Jessica
Ramallal, Raúl
Fitó, Montserrat
Salas Salvadó, Jordi
Metadata
Show full item record
Scientific Reports 11(1) : (2021) // Article ID 8719
Abstract
It remains unclear whether caffeinated beverages could have deleterious renal effects in elderly population with underlying comorbid conditions. We investigated the associations between coffee, tea, or caffeine intake and 1-year changes in glomerular filtration rate (eGFR) in a large Spanish cohort of overweight/obese elderly with metabolic syndrome (MetS). This prospective analysis includes 5851 overweight/obese adults (55–75 years) with MetS from the PREDIMED-Plus study. We assessed coffee, tea, and caffeine consumption from a validated food-frequency questionnaire and creatinine-based eGFR using the Chronic Kidney Disease Epidemiology Collaboration equation. Multivariate-adjusted regression models were applied to test associations between baseline coffee, tea, or caffeine intake and 1-year eGFR changes. Caffeinated coffee (> 2 cups/day) and tea (at least 1 cup/day) drinkers had 0.88 and 0.93 mL/min/1.73 m2 greater eGFR decrease respectively, compared to those with less than 1 cup/day of coffee consumption or non-tea drinkers. Furthermore, caffeinated coffee consumption of > 2 cups/day was associated with 1.19-fold increased risk of rapid eGFR decline > 3 mL/min/1.73 m2 (95% CI 1.01–1.41). Similarly, individuals in the highest (median, 51.2 mg/day) tertile of caffeine intake had a 0.87 mL/min/1.73 m2 greater eGFR decrease. Decaffeinated coffee was not associated with eGFR changes. In conclusion, higher consumption of caffeinated coffee, tea, and caffeine was associated with a greater 1-year eGFR decline in overweight/obese adults with MetS.